BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 10777217)

  • 1. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.
    Roth J; Koch P; Contente A; Dobbelstein M
    Oncogene; 2000 Mar; 19(14):1834-42. PubMed ID: 10777217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.
    Venot C; Maratrat M; Dureuil C; Conseiller E; Bracco L; Debussche L
    EMBO J; 1998 Aug; 17(16):4668-79. PubMed ID: 9707426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
    Seoane J; Le HV; Massagué J
    Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity.
    Zhu J; Jiang J; Zhou W; Zhu K; Chen X
    Oncogene; 1999 Mar; 18(12):2149-55. PubMed ID: 10321740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y.
    Pospísilová S; Siligan C; Ban J; Jug G; Kovar H
    Mol Cancer Res; 2004 May; 2(5):296-304. PubMed ID: 15192123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the p53 homolog p73 by adenoviral oncogene E1A.
    Das S; El-Deiry WS; Somasundaram K
    J Biol Chem; 2003 May; 278(20):18313-20. PubMed ID: 12639967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SSRP1 functions as a co-activator of the transcriptional activator p63.
    Zeng SX; Dai MS; Keller DM; Lu H
    EMBO J; 2002 Oct; 21(20):5487-97. PubMed ID: 12374749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p21/CDKN1A mediates negative regulation of transcription by p53.
    Löhr K; Möritz C; Contente A; Dobbelstein M
    J Biol Chem; 2003 Aug; 278(35):32507-16. PubMed ID: 12748190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
    Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
    Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How many mutant p53 molecules are needed to inactivate a tetramer?
    Chan WM; Siu WY; Lau A; Poon RY
    Mol Cell Biol; 2004 Apr; 24(8):3536-51. PubMed ID: 15060172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ING1 represses transcription by direct DNA binding and through effects on p53.
    Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
    Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue of mutant p53 transcription function by ellipticine.
    Peng Y; Li C; Chen L; Sebti S; Chen J
    Oncogene; 2003 Jul; 22(29):4478-87. PubMed ID: 12881704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
    Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
    Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
    Kong XT; Gao H; Stanbridge EJ
    J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p73 can suppress the proliferation of cells that express mutant p53.
    Willis AC; Pipes T; Zhu J; Chen X
    Oncogene; 2003 Aug; 22(35):5481-95. PubMed ID: 12934108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
    Baptiste N; Friedlander P; Chen X; Prives C
    Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased apoptosis induction by 121F mutant p53.
    Saller E; Tom E; Brunori M; Otter M; Estreicher A; Mack DH; Iggo R
    EMBO J; 1999 Aug; 18(16):4424-37. PubMed ID: 10449408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of the COOH-terminal region of p73alpha enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells.
    Ozaki T; Naka M; Takada N; Tada M; Sakiyama S; Nakagawara A
    Cancer Res; 1999 Dec; 59(23):5902-7. PubMed ID: 10606232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions.
    Edwards SJ; Hananeia L; Eccles MR; Zhang YF; Braithwaite AW
    Oncogene; 2003 Jul; 22(29):4517-23. PubMed ID: 12881708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.